🇺🇸 FDA
Patent

US 10485844

Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor

granted A61KA61K2039/505A61K2039/54

Quick answer

US patent 10485844 (Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor) held by REGENERON PHARMACEUTICALS, INC. expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
57
CPC classes
A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K38/00